PHAGE DISPLAYED CELL BINDING PEPTIDES

Abstract

A tryptophan cage binding domain polypeptide containing of all or part of amino acid sequence AAADX1YX2QWLX3X4X5GPX6SGRPPPX7 (SEQ ID NO: 4), wherein Xn represents an amino acid found in position n, the polypeptide comprising a tryptophan cage (Trp cage). A cell binding domain polypeptide having an amino acid sequence produced by phage display.

Description

Claims

1. An isolated polypeptide comprising all or part of amino acid sequence

2. The polypeptide of claim 1, wherein the polypeptide binds to human endothelial cells.

3. The polypeptide of claim 2, the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 447 to SEQ ID NO: 529, and SEQ ID NO: 541 to SEQ ID NO: 551, and SEQ ID NO: 586.

4. The polypeptide of claim 1 wherein the polypeptide binds to human epithelial cells.

5. The polypeptide of claim 4 wherein the polypeptide binds to human hepatic cells.

6. The polypeptide of claim 5, the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 201 to SEQ ID NO: 368.

7. The polypeptide of claim 1 wherein the polypeptide binds to a protein on the surface of a human cell.

8. The polypeptide of claim 1 wherein the polypeptide binds to a glycan on the surface of a human cell.

9. The polypeptide of claim 1 wherein the polypeptide conjugates or complexes with a biologically active agent.

10. The polypeptide of claim 9, wherein the biologically active agent is a drug.

11. The polypeptide of claim 10, wherein the biologically active agent is a siRNA molecule.

12. The polypeptide of claim 1, wherein the polypeptide conjugates or complexes with a fusogenic peptide.

13. The polypeptide of claim 12, wherein the fusogenic peptide is PN73.

14. A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 31 to SEQ ID NO: 529, and SEQ ID NO: 541 to SEQ ID NO: 551, and SEQ ID NO: 586.

15. The polypeptide of claim 14, wherein the polypeptide binds to human endothelial cells.

16. The polypeptide of claim 15, the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 369 to SEQ ID NO: 529, and SEQ ID NO: 541 to SEQ ID NO 551, and SEQ ID NO: 586.

17. The polypeptide of claim 14 wherein the polypeptide binds to human epithelial cells.

18. The polypeptide of claim 17 wherein the polypeptide binds to human hepatic cells.

19. The polypeptide of claim 18, the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 31 to SEQ ID NO: 368.

20. The polypeptide of claim 19, the polypeptide comprising the amino acid sequence NLQEFLF (SEQ ID NO: 61).

21. The polypeptide of claim 14 wherein the polypeptide binds to a protein on the surface of a human cell.

22. The polypeptide of claim 14 wherein the polypeptide binds to a glycan on the surface of a human cell.

23. The polypeptide of claim 14 wherein the polypeptide conjugates or complexes with a biologically active agent.

24. The polypeptide of claim 23, wherein the biologically active agent is a drug.

25. The polypeptide of claim 24, wherein the biologically active agent is a siRNA molecule.

26. The polypeptide of claim 14 wherein the polypeptide conjugates or complexes with a fusogenic peptide.

27. The polypeptide of claim 26, wherein the fusogenic peptide is PN73.

28. A method of using a polypeptide for delivering a drug to a specific tissue, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 31 to SEQ ID NO: 529, and SEQ ID NO: 541 to SEQ ID NO 551, and SEQ ID NO: 586.

29. The method of claim 28, wherein the polypeptide binds to a specific cell type within the tissue.

30. The method of claim 28, wherein the polypeptide is administered intravenously.

31. The method of claim 28, wherein the polypeptide is administered to the lung.

32. The method of claim 28, wherein the polypeptide is administered by injection.